Table 1.
Percentage of samples with positive T-cell responses against SARS-CoV-2 peptides (%).
| IFN-γ+ | IL-2+ | IFN-γ+ and/or IL-2+ | |
|---|---|---|---|
| Uninfected (n = 92) | 52/92 (56.5) | 59/92 (64.1) | 64/92 (70) |
| Unvaccinated (n = 20) | 3/20 (15) | 1/20 (5) | 4/20 (20) |
| Vaccinated (n = 72) | 49/72 (68) | 58/72 (81) | 60/72 (83) |
| Acute disease (n = 55) | 34/55 (61.9) | 31/55 (56.4) | 36/55 (65.4) |
| Mild (n = 5) | 2/5 (40) | 1/5 (20) | 2/5 (40) |
| Moderate (n = 4) | 2/4 (50) | 2/4 (50) | 3/4 (75) |
| Severe NIV (n = 31) | 22/31 (71) | 22/31 (71) | 23/31 (74.2) |
| Severe IMV (n = 8) | 6/8 (75) | 5/8 (62.5) | 6/8 (75) |
| Dead (n = 7) | 2/7 (28.6) | 1/7 (14.3) | 2/7 (28.6) |
| Convalescent (n = 97) | 80/97 (82.5) | 84/97 (86.6) | 87/97 (89.7) |
| Mild (n = 23)a | 15/23 (65.2) | 16/23 (69.6) | 17/23 (73.9) |
| Moderate (n = 19)a | 17/19 (89.5) | 16/19 (84.2) | 18/19 (94.7) |
| Severe NIV (n = 26)a | 21/26 (80.8) | 23/26 (88.5) | 23/26 (88.5) |
| Severe IMV (n = 29)a | 27/29 (93.1) | 29/29 (100) | 29/29 (100) |
Positivity percentages were calculated excluding the indeterminate results from the total number of samples tested for each group.
NIV non-invasive ventilation, IMV invasive mechanical ventilation.
aSeverity considered during their acute COVID-19 episode.